SAGE Therapeutics Inc. (SAGE)

140.55
NASDAQ : Health Technology
Prev Close 135.97
Day Low/High 136.45 / 142.14
52 Wk Low/High 79.88 / 193.56
Avg Volume 383.50K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 7.02B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics Announces Completion Of Enrollment For Phase 2 Proof-of-Concept Trial Of SAGE-547 In Severe Postpartum Depression

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that enrollment has been...

First Week of SAGE July 15th Options Trading

First Week of SAGE July 15th Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the July 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SAGE options chain for the new July 15th contracts and identified one put and one call contract of particular interest.

Monsanto, Amazon and Apple: Doug Kass' Views

Monsanto, Amazon and Apple: Doug Kass' Views

Doug Kass shares his thoughts on shorting financials, and wonders if it will be a Monsanto merger Monday.

Sage Therapeutics Announces First Quarter 2016 Financial Results

Sage Therapeutics Announces First Quarter 2016 Financial Results

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today reported business highlights and...

Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016

Sage Therapeutics To Report First Quarter 2016 Financial Results On Thursday, May 5, 2016

Sage Therapeutics, Inc. (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting

Sage Therapeutics Expands Scientific, Clinical And Burden Of Illness Data For SAGE-547 In SRSE And Essential Tremor At The 2016 American Academy Of Neurology Annual Meeting

Sage Therapeutics, Inc. (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced data from five abstracts to be...

Facebook, Ford and General Motors: Doug Kass' Views

Facebook, Ford and General Motors: Doug Kass' Views

Doug Kass shares his thoughts on two auto stocks and Facebook.

First Week of SAGE November 18th Options Trading

First Week of SAGE November 18th Options Trading

Investors in Sage Therapeutics Inc saw new options become available this week, for the November 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Sage Therapeutics, Inc. - SAGE

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sage Therapeutics, Inc.

Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Here’s Why Sage Therapeutics (SAGE) Stock is Tumbling Today

Sage Therapeutics (SAGE) stock is plunging on Wednesday after Kerrisdale Capital said it had shorted the stock and that its experimental drug would likely fail an important late stage study.

Tesla, Amazon and Netflix: Doug Kass' Views

Tesla, Amazon and Netflix: Doug Kass' Views

Doug Kass shares his views on why technicals bode ill for tech.

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

What Carl Icahn Is Doing; Biotech Breakout: Best of Kass

Doug Kass looks at Carl Icahn's actions on Apple and the breakout in biotech stocks.

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

JPMorgan, Deutsche Bank and Gilead Sciences: Doug Kass' Views

Doug Kass shares his views on the health of the banking sector and why he's buying biotech.

General Motors, MetLife and Tesla: Doug Kass' Views

General Motors, MetLife and Tesla: Doug Kass' Views

Doug Kass shares his views on why he's staying short of GM and MetLife despite steep declines in both stocks.

Sage Therapeutics Stock Sees Short Interest Jump 12%

Sage Therapeutics Stock Sees Short Interest Jump 12%

The most recent short interest data has been released by the NASDAQ for the 01/29/2016 settlement date, which shows a 288,977 share increase in total short interest for Sage Therapeutics Inc , to 2,679,665, an increase of 12.09% since 01/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547

SAGE Updates Guidance For Top-Line Results Of Phase 3 STATUS Trial Of SAGE-547

Top-Line Data Expected in Second Half of 2016 for SAGE's Global Phase 3 Trial in Super-Refractory Status Epilepticus

SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting

SAGE To Present Three Poster Presentations At The American Epilepsy Society 69th Annual Meeting

Sage Therapeutics (NASDAQ: SAGE) today announced upcoming medical/scientific poster presentations at the American Epilepsy Society 69 th Annual Meeting, taking place from December 4-8, 2015 at the Pennsylvania...

TheStreet Quant Rating: D (Sell)